Omarigliptin Prevents TNF-α-Induced Cellular Senescence in Rat Aorta Vascular Smooth Muscle Cells.

Cellular senescence is one of the most significant factors involved in aging and age-related diseases. Senescence of vascular smooth muscle cells (VSMCs) adversely affects the function of the cardiovascular system and contributes to the development of atherosclerosis, hypertension, and other cardiovascular diseases. Glucagon-like peptide-1 (GLP-1) is an important incretin hormone involved in insulin release and vascular tone. GLP-1 is quickly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Omarigliptin is a new DPP-4 inhibitor that has demonstrated anti-inflammatory and antioxidative stress properties. In the present study, we investigated the effects of the selective DPP-4 inhibitor omarigliptin (OMG) on VSMCs exposed to insult from tumor necrosis factor-α (TNF-α), one of the main inflammatory signaling molecules involved in cellular senescence. We found that OMG could suppress TNF-α-induced expression of pro-inflammatory cytokines (interleukin-1β (IL-1β), IL-6, and IL-8) and inhibit oxidative stress by reducing the production of H2O2 and protein carbonyl. OMG ameliorated the increase in senescence-associated β-galactosidase (SA-β-gal) and telomerase activity induced by TNF-α. The plasminogen activator inhibitor-1 (PAI-1)/p53/p21 pathway is a key inducer of cellular senescence. OMG ameliorated the acetylation of p53 at lysine 382 (K382) and subsequent activation of p21 via inhibition of PAI-1. Importantly, our experiments revealed that blockage of silent information-regulator 1 (SIRT1) abolished the inhibitory effects of OMG on p53 acetylation, SA-β-gal activity, and telomerase activity in VSMCs. These results suggest that OMG may have the potential to delay or prevent the progression of age-related cardiovascular diseases by modulating the activity of SIRT1.

[1]  Shaoshuang Wang,et al.  Omarigliptin Mitigates Lipopolysaccharide-Induced Neuroinflammation and Dysfunction of the Integrity of the Blood-Brain Barrier. , 2020, ACS chemical neuroscience.

[2]  R. Park,et al.  Isoparvifuran isolated from Dalbergia odorifera attenuates H2O2-induced senescence of BJ cells through SIRT1 activation and AKT/mTOR pathway inhibition. , 2020, Biochemical and biophysical research communications.

[3]  D. Sedding,et al.  Inflammatory Drivers of Cardiovascular Disease: Molecular Characterization of Senescent Coronary Vascular Smooth Muscle Cells , 2020, Frontiers in Physiology.

[4]  Byung-Min Choi,et al.  Latifolin inhibits oxidative stress-induced senescence via upregulation of SIRT1 in human dermal fibroblasts. , 2020, Biological & pharmaceutical bulletin.

[5]  S. Hattori.  Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes , 2020, Diabetology & Metabolic Syndrome.

[6]  Yuchen Ge,et al.  SIRT1 and aging related signaling pathways , 2020, Mechanisms of Ageing and Development.

[7]  E. S. Kang,et al.  Duck Oil-loaded Nanoemulsion Inhibits Senescence of Angiotensin II-treated Vascular Smooth Muscle Cells by Upregulating SIRT1 , 2020, Food science of animal resources.

[8]  X. Cheng,et al.  Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation. , 2019, Chemico-biological interactions.

[9]  J. Papaconstantinou.  The Role of Signaling Pathways of Inflammation and Oxidative Stress in Development of Senescence and Aging Phenotypes in Cardiovascular Disease , 2019, Cells.

[10]  Yu Zhou,et al.  Exendin-4 enhances proliferation of senescent osteoblasts through activation of the IGF-1/IGF-1R signaling pathway. , 2019, Biochemical and biophysical research communications.

[11]  Leilei Wu,et al.  Protective effect of vildagliptin on TNF‐α‐induced chondrocyte senescence , 2019, IUBMB life.

[12]  F. Shen,et al.  Vascular smooth muscle cell senescence and age-related diseases: State of the art. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[13]  Xiaoting Liang,et al.  TGF-β mediates aortic smooth muscle cell senescence in Marfan syndrome , 2019, Aging.

[14]  Tiechao Jiang,et al.  Anagliptin ameliorates high glucose‐ induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1 , 2019, Molecular immunology.

[15]  Li-Ping Liu,et al.  DPP‐4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells under hypoxic/high‐glucose conditions, potentially through the SIRT1/HIF‐1/VEGF pathway , 2018, CNS neuroscience & therapeutics.

[16]  K. Hosoda,et al.  Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study , 2018, Diabetology International.

[17]  Dongyin Zhang,et al.  Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway. , 2017, International journal of molecular medicine.

[18]  P. Home,et al.  A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. , 2017, Diabetes research and clinical practice.

[19]  Dan Yang,et al.  GLP-1 and Ghrelin Attenuate High Glucose/High Lipid-Induced Apoptosis and Senescence of Human Microvascular Endothelial Cells , 2017, Cellular Physiology and Biochemistry.

[20]  A. Ballestrero,et al.  5‐fluorouracil causes endothelial cell senescence: potential protective role of glucagon‐like peptide 1 , 2017, British journal of pharmacology.

[21]  S. Engel,et al.  A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus , 2017, Cardiovascular Diabetology.

[22]  Kotb Abdelmohsen,et al.  Identification of senescent cell surface targetable protein DPP4 , 2017, Genes & development.

[23]  Gang Liu,et al.  Serpine 1 induces alveolar type II cell senescence through activating p53‐p21‐Rb pathway in fibrotic lung disease , 2017, Aging cell.

[24]  C. Powell,et al.  Resveratrol: An Epigenetic Regulator of SIRT1 – Is It a Magic Tool to Prevent Cardiovascular Disease? , 2017 .

[25]  A. Gourine,et al.  Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning , 2016, Cardiovascular research.

[26]  D. Koya,et al.  Aging (albany Ny) , 2022 .

[27]  J. Zhan,et al.  The PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs , 2016, Molecular and Cellular Biochemistry.

[28]  G. Nixon,et al.  Sphingosylphosphorylcholine inhibits macrophage adhesion to vascular smooth muscle cells , 2016, Biochemical pharmacology.

[29]  Chao-Yung Wang,et al.  Telomeres and Telomerase in Cardiovascular Diseases , 2016, Genes.

[30]  V. Demarco,et al.  Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice , 2016, Cardiovascular Diabetology.

[31]  T. Hirano,et al.  Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals , 2016, Journal of diabetes investigation.

[32]  Luca Tiano,et al.  Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells , 2016, Oncotarget.

[33]  J. Zhan,et al.  The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. , 2015, International journal of cardiology.

[34]  Aiqin Li,et al.  Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. , 2014, American journal of physiology. Cell physiology.

[35]  Mirla Fiuza Diniz,et al.  Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. , 2013, Archives of medical research.

[36]  X. Lv,et al.  SIRT1 as a novel potential treatment target for vascular aging and age-related vascular diseases. , 2012, Current molecular medicine.

[37]  J. Tuomilehto.  Impact of age on cardiovascular risk: implications for cardiovascular disease management. , 2004, Atherosclerosis. Supplements.